Indoprofen

Identification

Name
Indoprofen
Accession Number
DB08951
Type
Small Molecule
Groups
Withdrawn
Description

A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
CPE46ZU14N
CAS number
31842-01-0
Weight
Average: 281.3059
Monoisotopic: 281.105193351
Chemical Formula
C17H15NO3
InChI Key
RJMIEHBSYVWVIN-UHFFFAOYSA-N
InChI
InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)
IUPAC Name
2-[4-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)phenyl]propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Glucuronidation.

Route of elimination
Not Available
Half life

2.3 hours.

Clearance

Renal.

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Indoprofen.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Indoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabIndoprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololIndoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolIndoprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Indoprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid.Approved
AliskirenIndoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alminoprofen.Experimental
AlprenololIndoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Indoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Amcinonide.Approved
AmikacinIndoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideIndoprofen may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Aminosalicylic Acid.Approved
AmiodaroneIndoprofen may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodIndoprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Indoprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Indoprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Indoprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanIndoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Antrafenine.Approved
ApixabanIndoprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Indoprofen is combined with Apocynin.Investigational
ApramycinIndoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Indoprofen.Approved, Investigational
ArbekacinIndoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinIndoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIndoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololIndoprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineIndoprofen may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Atamestane.Investigational
AtenololIndoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indoprofen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Indoprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indoprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Indoprofen.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Balsalazide.Approved, Investigational
BecaplerminIndoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololIndoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinIndoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indoprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Indoprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Indoprofen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololIndoprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Indoprofen.Approved, Investigational
BevantololIndoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indoprofen.Approved, Investigational
BisoprololIndoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIndoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololIndoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bucillamine.Investigational
BucindololIndoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bufexamac.Approved, Experimental
BufuralolIndoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Indoprofen.Approved
BupranololIndoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Indoprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Indoprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololIndoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIndoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Indoprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Celecoxib.Approved, Investigational
CeliprololIndoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinIndoprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Indoprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indoprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cimicoxib.Investigational
CinoxacinIndoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinIndoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cisplatin.Approved
Citric AcidIndoprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Indoprofen.Vet Approved
CloranololIndoprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Indoprofen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indoprofen.Experimental
CyclosporineIndoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateIndoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIndoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIndoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIndoprofen may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Indoprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Indoprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Delapril.Experimental
DesipramineIndoprofen may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinIndoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indoprofen.Approved, Investigational
DextranIndoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinIndoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indoprofen.Approved, Vet Approved
DicoumarolIndoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Indoprofen is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Indoprofen.Approved
DihydrostreptomycinIndoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Indoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indoprofen.Approved
DrospirenoneIndoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Indoprofen is combined with E-6201.Investigational
Edetic AcidIndoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIndoprofen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Indoprofen is combined with Enalaprilat.Approved
EnoxacinIndoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinIndoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Indoprofen.Experimental
EpanololIndoprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Indoprofen is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Indoprofen.Experimental
EplerenoneIndoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Indoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Equilin.Approved
EsatenololIndoprofen may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololIndoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indoprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateIndoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Indoprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Indoprofen.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Indoprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Feprazone.Experimental
Ferulic acidIndoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indoprofen.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fish oil.Approved, Nutraceutical
FleroxacinIndoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Indoprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneIndoprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineIndoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Indoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxIndoprofen may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumIndoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Indoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fosinopril.Approved
FramycetinIndoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Indoprofen.Approved, Vet Approved
GabexateIndoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIndoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIndoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Indoprofen.Approved, Withdrawn
GemifloxacinIndoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIndoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinIndoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIndoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinIndoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Indoprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Indoprofen is combined with HE3286.Investigational
HeparinIndoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Higenamine.Investigational
HydralazineIndoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indoprofen.Approved, Investigational
Hygromycin BIndoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Indoprofen.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Indoprofen is combined with Icosapent.Approved, Nutraceutical
IdraparinuxIndoprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indoprofen.Approved
IndenololIndoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Indomethacin.Approved, Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indoprofen.Approved, Investigational
IsepamicinIndoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Indoprofen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Indoprofen is combined with Istaroxime.Investigational
KanamycinIndoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Indoprofen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indoprofen.Approved
LabetalolIndoprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololIndoprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indoprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Indoprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Indoprofen.Approved, Investigational
LepirudinIndoprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIndoprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololIndoprofen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololIndoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIndoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Indoprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Indoprofen.Approved
LomefloxacinIndoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Indoprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Indoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indoprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Indoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mefenamic acid.Approved
MelagatranIndoprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Meloxicam.Approved, Vet Approved
MepindololIndoprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Indoprofen.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Indoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololIndoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen.Approved
MetoprololIndoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinIndoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Indoprofen.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indoprofen.Approved
MoxifloxacinIndoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indoprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nabumetone.Approved
NadololIndoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinIndoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatIndoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Indoprofen.Approved
Nalidixic AcidIndoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Indoprofen is combined with NCX 1022.Investigational
NeamineIndoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololIndoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinIndoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinIndoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nepafenac.Approved, Investigational
NetilmicinIndoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nitroaspirin.Investigational
NorfloxacinIndoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinIndoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indoprofen.Approved
OlsalazineIndoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Indoprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Indoprofen is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Orgotein.Vet Approved
OtamixabanIndoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Oxaprozin.Approved
Oxolinic acidIndoprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIndoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indoprofen.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Parecoxib.Approved
ParomomycinIndoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Parthenolide.Approved, Investigational
PazufloxacinIndoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIndoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIndoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateIndoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateIndoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Perindopril.Approved
PhenindioneIndoprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonIndoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indoprofen.Approved, Investigational
PindololIndoprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidIndoprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Indoprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indoprofen.Approved, Investigational
Piromidic acidIndoprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorIndoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinIndoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indoprofen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pomalidomide.Approved
Potassium CitrateIndoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololIndoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Indoprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Indoprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Propacetamol.Approved, Investigational
PropafenoneIndoprofen may decrease the antihypertensive activities of Propafenone.Approved
PropranololIndoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Indoprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Indoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Indoprofen.Vet Approved
Protein CIndoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanIndoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIndoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinIndoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Indoprofen.Investigational
PuromycinIndoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indoprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinIndoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinIndoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanIndoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinIndoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinIndoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Indoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Indoprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Indoprofen.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Indoprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indoprofen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Indoprofen is combined with Serrapeptase.Investigational
SisomicinIndoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinIndoprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateIndoprofen may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Indoprofen.Approved
SotalolIndoprofen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinIndoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Spirapril.Approved
SpironolactoneIndoprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Indoprofen.Investigational
StreptomycinIndoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Indoprofen is combined with Sulindac.Approved, Investigational
SulodexideIndoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Indoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Suxibuzone.Experimental
TacrolimusIndoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Indoprofen.Approved
TalinololIndoprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Indoprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Indoprofen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indoprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indoprofen.Approved, Investigational
TemafloxacinIndoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tepoxalin.Vet Approved
TerbutalineIndoprofen may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Indoprofen.Approved
TertatololIndoprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololIndoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinIndoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Indoprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Indoprofen.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIndoprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indoprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Indoprofen is combined with Trolamine salicylate.Approved
TrovafloxacinIndoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinIndoprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indoprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Indoprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indoprofen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Indoprofen.Approved
WarfarinIndoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIndoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Indoprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Indoprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Indoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indoprofen.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,767,805.

General References
  1. Sivelli R, Farinon AM, Ghirarduzzi A, Rinetti M: Duodenogastric reflux and gastric damage from non-steroidal antiinflammatory drugs. Int J Tissue React. 1986;8(1):61-6. [PubMed:3949444]
External Links
KEGG Drug
D04530
PubChem Compound
3718
PubChem Substance
310264916
ChemSpider
3587
BindingDB
50233673
ChEBI
76162
ChEMBL
CHEMBL15870
Wikipedia
Indoprofen
ATC Codes
M01AE10 — Indoprofen

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)208-210U.S. Patent 3,767,805.
Predicted Properties
PropertyValueSource
Water Solubility0.128 mg/mLALOGPS
logP2.44ALOGPS
logP2.86ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.74ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity79.14 m3·mol-1ChemAxon
Polarizability30.24 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3790000000-98b2b4d927ad1042f83f

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Isoindolones / Isoindoles / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Lactams / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
2-phenylpropanoic-acid / Isoindolone / Isoindoline / Isoindole / Isoindole or derivatives / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Carboxamide group / Lactam
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid, gamma-lactam, isoindoles (CHEBI:76162)

Drug created on May 27, 2014 13:29 / Updated on June 02, 2018 08:14